Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General Hospital
![Thumbnail](/xmlui/bitstream/handle/10234/164618/Llueca_2016_Effectiveness.pdf.jpg?sequence=6&isAllowed=y)
Visualitza/
Impacte
![Google Scholar](/xmlui/themes/Mirage2/images/uji/logo_google.png)
![Microsoft Academico](/xmlui/themes/Mirage2/images/uji/logo_microsoft.png)
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadades
Títol
Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General HospitalAutoria
Data de publicació
2016Editor
Elmer PressCita bibliogràfica
LLUECA ABELLA, José Antonio; HERRÁIZ RODA, José Luis; CATALÀ MASÓ, Carmen; SERRA, Anna; RIVADULLA, Isabel; ESCRIG SOS, Javier. Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General Hospital. Journal of Clinical Gynecology and Obstetrics (2015), v 4, n. 3, pp. 251-257Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
http://www.jcgo.org/index.php/jcgo/article/view/345Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Background: The aim of the study was to evaluate the initial efficiency
and security of maximal effort cytoreductive surgery in stages
III and IV of ovarian cancer at a university hospital.
Methods: Thirty-four ... [+]
Background: The aim of the study was to evaluate the initial efficiency
and security of maximal effort cytoreductive surgery in stages
III and IV of ovarian cancer at a university hospital.
Methods: Thirty-four patients with stage III and IV ovarian carcinoma
underwent surgery between January 2013 and June 2014 in
the University General Hospital of Castellon (Spain). Patients with
primary and relapse ovarian cancer were included. The extent of disease,
type of surgical technique, amount of tumor prior to surgery and
amount of residual disease after surgery were recorded. To quantify
the efficiency and the security of the procedure, the complete cytoreduction
and the morbidity and the mortality rates were described.
Results: Of the patients 26.4% received neoadjuvant chemotherapy.
Complete cytoreductive surgery, without evident residual tumor at the
end of the procedure, was obtained in 79% of patients and optimal cytoreductive
surgery (CC0-CC1) in 91%. Surgical complications were
found in 56% of patients and two deaths (6%) occurred attributable to
surgery. The disease free interval was 15 months.
Conclusions: This study confirms that with experienced multidisciplinary
teams and in tertiary referral hospitals, 79% of complete
cytoreduction surgery in advanced ovarian cancer can be achieved
but they must be prepared to deal with a high rate of complications [-]
Publicat a
Journal of Clinical Gynecology and Obstetrics (2015), v 4, n. 3Drets d'accés
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Apareix a les col.leccions
- MED_Articles [657]